Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Next-Generation Gene Therapy: Few disciplines in contemporary clinical research have experienced the high expectations directed at the gene therapy field. However, gene therapy has been challenging to translate to the clinic, often because the therapeutic gene is expressed at insufficient levels in the patient or because the gene delivery vector integrates near protooncogenes, which can cause leukemia (see the Perspective by Verma ). Biffi et al. ( 1233158 , published online 11 July) and Aiuti et al. ( 1233151 ; published online 11 July) report progress on both fronts in gene therapy trials of three patients with metachromatic leukodystrophy (MLD), a neurodegenerative disorder, and three patients with Wiskott-Aldrich syndrome (WAS), an immunodeficiency disorder. Optimized lentiviral vectors were used to introduce functional MLD or WAS genes into the patients' hematopoietic stem cells (HSCs) ex vivo, and the transduced cells were then infused back into the patients, who were then monitored for up to 2 years. In both trials, the patients showed stable engraftment of the transduced HSC and high expression levels of functional MLD or WAS genes. Encouragingly, there was no evidence of lentiviral vector integration near proto-oncogenes, and the gene therapy treatment halted disease progression in most patients. A longer follow-up period will be needed to further validate efficacy and safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [68]
In the citing paper
“However, the clonal integration site expansions do not appear to be related to oncogenic selection [54].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [54]
In the citing paper
“In the CF clinical field recent pre-clinical studies provided encouraging results on lentiviral-mediated CFTR delivery which are leading to the preparation of a first-in-man lentivirus trial in patients with CF11,57.”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [57]
In the citing paper
“Unlike the retroviral vectors used in those studies, the Lenti-D lentiviral vector (as well as other lentiviral and gamma-retro-viral vectors that are enhancer-deleted with the use of a self-inactivating vector design) so far appears to reduce the risk of mutagenesis.29–32”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [31]
Citations
Cites
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“Recent studies in mice have shown that microglia mostly originates from an early seeding of neural tissues by embryonic lineage macrophages followed by in situ turnover under homeostatic conditions (32).”
BackgroundIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 4×
“Hematopoietic stem cell transplantation (HSCT) and HSC gene therapy (HSC-GT) have been investigated for the treatment of lysosomal storage diseases because enzyme-proficient hematopoietic progeny cells can migrate to the affected tissues, including the CNS, scavenge the stored material, such as sulfatide in MLD, and c…”
BackgroundInfluentialSelf-citationLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Self-citationInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“(HSPCs) has the potential to trigger leukemia through insertionalmutagenesis (14, 18).”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 3×
“These gene classes were the same, or shared >75% genes, with gene classes overrepresented in the ALD HSC-GT (17, 29) (Fig.”
BackgroundMethodSelf-citationHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationTHE GROSS MOTOR FUNCTION MEASURE: A MEANS TO EVALUATE THE EFFECTS OF PHYSICAL THERAPY
Russell, D. J., Rosenbaum, P. L., Cadman, D. T., Gowland, C., Hardy, S., & Jarvis, S. (1989) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1989.tb04003.x · Cited by 1,035
Research works printed but not linked: 1
- 10.1002/(SICI)1098-1004(1997)9:3<234::AID-HUMU4>3.0.CO;2-7 · doi:10.1002/(sici)1098-1004(1997)9:3<234::aid-humu4>3.0.co;2-7
Cited by
Microglia Biology: One Century of Evolving Concepts
Prinz, M., Jung, S., & Priller, J. (2019) · Cell · doi:10.1016/j.cell.2019.08.053 · Cited by 1,525
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“leukodystrophy LV ARSA (117, 154) San Raffaele Telethon Institute of”
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Self-citationGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Shemer, A., Grozovski, J., Tay, T. L., Tao, J., Volaski, A., Süß, P., Ardura-Fabregat, A., Gross-Vered, M., Kim, J.-S., David, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07548-5 · Cited by 1,052
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Self-citationMyelination of the Nervous System: Mechanisms and Functions
Nave, K.-A., & Werner, H. B. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013101 · Cited by 983
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Targeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
“Hematopoietic Stem Cells (HSC)-based gene therapy has provided therapeutic benefit in primary immunodeficiencies 1,2 , thalassemia 3 and leukodystrophies 4,5 .”
Self-citationHigh, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Self-citationA combination of ontogeny and CNS environment establishes microglial identity
Bennett, F. C., Bennett, M. L., Yaqoob, F., Mulinyawe, S. B., Grant, G. A., Hayden Gephart, M., Plowey, E. D., & Barres, B. A. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.014 · Cited by 524
“Do microglia permanently change their identity following disease, or can they return to a homeostatic state? Like YS-derived cells, can macrophages derived from HSCs become microglia? The answers are critical not only to how microglia and infiltrating myeloid cells affect the brain, but also to the growing use of myel…”
InfluentialSessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502
Self-citationInheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., & Lombardo, A. (2016) · Cell · doi:10.1016/j.cell.2016.09.006 · Cited by 516
Self-citationEntering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
Surface-Engineered Dendrimers in Gene Delivery
Yang, J., Zhang, Q., Chang, H., & Cheng, Y. (2015) · Chemical Reviews · doi:10.1021/cr500542t · Cited by 429
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“The lentiviral-HSC therapy causes a normalization of ASA levels in the CSF (Biffi et al., 2013).”
BackgroundLysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
van der Knaap, M. S., & Bugiani, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1739-1 · Cited by 403
“1 3 based on genetic modification of autologous hematopoietic stem cells to express or over-express the ASA enzyme, is a promising option, but predictability of gene-transduction efficacy and engraftment of transduced cells must be optimized [18, 198].”
BackgroundTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Aldenhoven, M., Wynn, R. F., Orchard, P. J., O’Meara, A., Veys, P., Fischer, A., Valayannopoulos, V., Neven, B., Rovelli, A., Prasad, V. K., et al. (2015) · Blood · doi:10.1182/blood-2014-11-608075 · Cited by 321
Self-citationPrimary Cilia in the Developing and Mature Brain
Guemez-Gamboa, A., Coufal, N. G., & Gleeson, J. G. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.024 · Cited by 296
“Lentivirus has recently been proven beneficial for gene therapy against childhood lysosomal disorders (Aiuti et al., 2013; Biffi et al., 2013); however, lentivirus has not yet been widely utilized for gene delivery in ciliopathies except for”
Fumagalli, F., Calbi, V., Natali Sora, M. G., Sessa, M., Baldoli, C., Rancoita, P. M. V., Ciotti, F., Sarzana, M., Fraschini, M., Zambon, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02017-1 · Cited by 298
Self-citationProduction of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Synthetic biology in mammalian cells: next generation research tools and therapeutics
Lienert, F., Lohmueller, J. J., Garg, A., & Silver, P. A. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3738 · Cited by 280
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Lancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Wang, J., Exline, C. M., DeClercq, J. J., Llewellyn, G. N., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Surosky, R. T., Gregory, P. D., Holmes, M. C., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3408 · Cited by 261
Ferreira, C. R., & Gahl, W. A. (2017) · Translational Science of Rare Diseases · doi:10.3233/trd-160005 · Cited by 263
De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3480 · Cited by 258
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Self-citationLentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency
De Ravin, S. S., Wu, X., Moir, S., Kardava, L., Anaya-O’Brien, S., Kwatemaa, N., Littel, P., Theobald, N., Choi, U., Su, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8856 · Cited by 244
Biasco, L., Pellin, D., Scala, S., Dionisio, F., Basso-Ricci, L., Leonardelli, L., Scaramuzza, S., Baricordi, C., Ferrua, F., Cicalese, M. P., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.04.016 · Cited by 243
Self-citationGene Insertion Into Genomic Safe Harbors for Human Gene Therapy
Papapetrou, E. P., & Schambach, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.38 · Cited by 238
The rapidly evolving view of lysosomal storage diseases
Parenti, G., Medina, D. L., & Ballabio, A. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012836 · Cited by 230
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency
Kohn, D. B., Booth, C., Shaw, K. L., Xu-Bayford, J., Garabedian, E., Trevisan, V., Carbonaro-Sarracino, D. A., Soni, K., Terrazas, D., Snell, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2027675 · Cited by 217
Self-citationMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
De Ravin, S. S., Reik, A., Liu, P.-Q., Li, L., Wu, X., Su, L., Raley, C., Theobald, N., Choi, U., Song, A. H., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3513 · Cited by 195
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“…virus (AAV) vectors (Pierce and Bennett, 2015); curtailment of further brain neurodegeneration in the brain in metachromatic leukodystrophy (MLD) (Biffi et al., 2013) and adrenoleukodystrophy (ALD) (Cartier and Aubourg, 2010) using ex vivo genetic modification of hematopoietic stem cells with…”
BackgroundInfluentialUncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Self-citationBiasco, L., Scala, S., Basso Ricci, L., Dionisio, F., Baricordi, C., Calabria, A., Giannelli, S., Cieri, N., Barzaghi, F., Pajno, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010314 · Cited by 175
Self-citationHematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome
Gentner, B., Tucci, F., Galimberti, S., Fumagalli, F., De Pellegrin, M., Silvani, P., Camesasca, C., Pontesilli, S., Darin, S., Ciotti, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106596 · Cited by 171
Self-citationHematopoietic Stem Cells and Their Roles in Tissue Regeneration
Lee, J. Y., & Hong, S.-H. (2020) · International Journal of Stem Cells · doi:10.15283/ijsc19127 · Cited by 165
“furthermore, improved techniques, such as gene transfer with HSCT, could be used to treat a variety of diseases (31).”
BackgroundLiver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158
“We produced three large-scale batches of lentiviral vectors according to a manufacturing process previously developed for clinical-grade lentiviral vectors (19, 20).”
BackgroundMethodSelf-citationHsieh, M. M., Bonner, M., Pierciey, F. J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M. C., Thompson, A. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001330 · Cited by 152
Self-citationPreparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G., & Aiuti, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28762-2 · Cited by 145
Self-citationMutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy
Cesani, M., Lorioli, L., Grossi, S., Amico, G., Fumagalli, F., Spiga, I., Filocamo, M., & Biffi, A. (2016) · Human Mutation · doi:10.1002/humu.22919 · Cited by 135
Self-citationNegre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., et al. (2014) · Current Gene Therapy · doi:10.2174/1566523214666141127095336 · Cited by 126
Self-citationConstruction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Enhancers Are Major Targets for Murine Leukemia Virus Vector Integration
De Ravin, S. S., Su, L., Theobald, N., Choi, U., Macpherson, J. L., Poidinger, M., Symonds, G., Pond, S. M., Ferris, A. L., Hughes, S. H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00011-14 · Cited by 103
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
Gene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91
“A therapeutic strategy that could make stem cell therapy a more viable option for MLD combines HSC transplants with gene therapy (Biffi et al., 2013).”
BackgroundGolebiowski, D., van der Bom, I. M. J., Kwon, C.-S., Miller, A. D., Petrosky, K., Bradbury, A. M., Maitland, S., Kühn, A. L., Bishop, N., Curran, E., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.109 · Cited by 87
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
Piras, F., Riba, M., Petrillo, C., Lazarevic, D., Cuccovillo, I., Bartolaccini, S., Stupka, E., Gentner, B., Cittaro, D., Naldini, L., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707922 · Cited by 75
Self-citationThe changing face of adrenoleukodystrophy
Zhu, J., Eichler, F., Biffi, A., Duncan, C. N., Williams, D. A., & Majzoub, J. A. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa013 · Cited by 78
Self-citationCarbonaro, D. A., Zhang, L., Jin, X., Montiel-Equihua, C., Geiger, S., Carmo, M., Cooper, A., Fairbanks, L., Kaufman, M. L., Sebire, N. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.265 · Cited by 78
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
“Although a definitive conclusion on the results must await the long-term observations, the data presented in both the MLD and WAS clinical trials support the idea that lentiviral vector-based gene therapy is a safer alternative, compared with the gene transfer approach employing γ-retroviruses (Aiuti et al., 2013; Bif…”
BackgroundMethodResultInfluentialBrendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
“deaminase deficiency,(15) X-linked severe combined immunodeficiency (SCID), X-linked chronic granulomatous disease,(19) Wiskott-Aldrich syndrome,(20,21) childhood cerebral adrenoleukodystrophy,(22,23) and metachromatic leukodystrophy.(24) More recently, ex vivo lentiviral vector (LVV)-based gene therapy has shown prom…”
BackgroundMilani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“However, the cell line-produced LV still allowed reaching clinically relevant VCN in the HSPC (Aiuti et al, 2013; Biffi et al, 2013).”
BackgroundMethodResultSelf-citationDevelopment of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
von Jonquieres, G., Fröhlich, D., Klugmann, C. B., Wen, X., Harasta, A. E., Ramkumar, R., Spencer, Z. H. T., Housley, G. D., & Klugmann, M. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00013 · Cited by 61
“…matter disorders caused by genetic deficiencies in oligodendrocyte proteins, have been trialled successfully by ex vivo gene therapy acting via cross-correction of dysfunctional oligodendrocytes by uptake of graft-derived, secreted transgene products (Cartier et al., 2009; Biffi et al., 2013).”
BackgroundDesign and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60
“For example, early clinical trials have shown evidence of disease correction or delay of onset including treatment for thalassemia, adrenoleukodystrophy, chronic lymphocytic leukemia, metachromatic leukodystrophy, and Wiskott Aldrich syndrome [9–13].”
BackgroundLentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
“The majority involve the ex vivo treatment of hematopoietic stem cells for monogenetic diseases (>350 patients and 1000 patient-years, based on review of current and completed clinical trials utilizing lentiviral vectors), including SCID-X1 [133], adrenoleukodystrophy (ALD) [134], metachromatic leukodystrophy (MLD) [1…”
BackgroundInfluentialRosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
“Results from a clinical trial in patients with late infantile MLD, using allogeneic, autologous lentivirus-mediated genetically modified hematopoietic stem cells expressing ARSA, suggest that the disease progression can be halted if treatment is administered early to presymptomatic patients (Biffi et al., 2013).”
BackgroundGenetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
“One approach is based on targeting the CFTR splicing mutation 3849+10kb C-to-T mutation which results in the inclusion of an 84 base-pair (bp) cryptic exon containing a premature termination codon between exons 22 and 23.”
De Ravin, S. S., Liu, S., Sweeney, C. L., Brault, J., Whiting-Theobald, N., Ma, M., Liu, T., Choi, U., Lee, J., O’Brien, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31344-x · Cited by 51
Biavasco, R., Lettera, E., Giannetti, K., Gilioli, D., Beretta, S., Conti, A., Scala, S., Cesana, D., Gallina, P., Norelli, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24876-1 · Cited by 47
Self-citationAberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque
Espinoza, D. A., Fan, X., Yang, D., Cordes, S. F., Truitt, L. L., Calvo, K. R., Yabe, I. M., Demirci, S., Hope, K. J., Hong, S. G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.003 · Cited by 46
Mattar, C. N., Wong, A. M. S., Hoefer, K., Alonso-Ferrero, M. E., Buckley, S. M. K., Howe, S. J., Cooper, J. D., Waddington, S. N., Chan, J. K. Y., & Rahim, A. A. (2015) · The FASEB Journal · doi:10.1096/fj.14-269092 · Cited by 46
“Ex vivo gene-therapy–augmented HSCTbased treatment is also attractive because of its potential to tackle CNS pathology, mediated by restoration of healthy microglia that cross into the brain and secrete therapeutic enzymes and has been highly effective in patients who have X-linked adrenoleukodystrophy (4) and metachr…”
BackgroundLong-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
Bougnères, P., Hacein-Bey-Abina, S., Labik, I., Adamsbaum, C., Castaignède, C., Bellesme, C., & Schmidt, M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.053 · Cited by 45
“10,11,14,16 Apart from eminent KDM2A and PACS1 , the most prominent clusters included CCND2-AS1 , MECOM , and SMG6 (Fig.”
Self-citationRosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Gene therapy for blood diseases
Kohn, D. B. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.11.016 · Cited by 39
State of the art: gene therapy of haemophilia
Spencer, H. T., Riley, B. E., & Doering, C. B. (2016) · Haemophilia · doi:10.1111/hae.13011 · Cited by 36
Gene therapy for lysosomal storage diseases and peroxisomal diseases
Ohashi, T. (2019) · Journal of Human Genetics · doi:10.1038/s10038-018-0537-5 · Cited by 31
Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.028 · Cited by 18
Self-citationGene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
Pelizaeus–Merzbacher disease: on the cusp of myelin medicine
Elitt, M. S., & Tesar, P. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.005 · Cited by 16
AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement
Golebiowski, D., Bradbury, A. M., Kwon, C.-S., van der Bom, I. M. J., Stoica, L., Johnson, A. K., Wilson, D. U., Gray-Edwards, H. L., Hudson, J. A., Johnson, J. A., et al. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_11 · Cited by 6
Luostarinen, A., Kailaanmäki, A., Turkki, V., Köylijärvi, M., Käyhty, P., Leinonen, H., Albers-Skirdenko, V., Lipponen, E., Ylä-Herttuala, S., Kaartinen, T., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.04.002 · Cited by 6
Metadata
- Authors
- Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., Benedicenti, F., Vallanti, G., Biasco, L., Leo, S., Kabbara, N., Zanetti, G., Rizzo, W. B., Mehta, N. A. L., Cicalese, M. P., Casiraghi, M., Boelens, J. J., Del Carro, U., Dow, D. J., Schmidt, M., Assanelli, A., Neduva, V., Di Serio, C., Stupka, E., Gardner, J., von Kalle, C., Bordignon, C., Ciceri, F., Rovelli, A., Roncarolo, M. G., Aiuti, A., Sessa, M., & Naldini, L.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- Vita-Salute San Raffaele University (IT)
- University of Perugia (IT)
- MolMed (Italy) (IT)
- Center for Advanced Studies Research and Development in Sardinia (IT)
- Rafik Hariri University Hospital (LB)
- University of Nebraska Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- University Medical Center Utrecht (NL)
- Neurology Unit, Department of Neurology, San Raffaele Scientific Institute, 20132 Milan, Italy.
- German Cancer Research Center (DE)
- Vita-Salute San Raffaele University, 20132 Milan, Italy.
- GlaxoSmithKline (United States) (US)
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany.
- Azienda Ospedaliera San Gerardo (IT)
- University of Rome Tor Vergata (IT)
- Corresponding author
- Biffi, Alessandra
- Montini, Eugenio
- Naldini, Luigi
- ORCID
- Biffi, Alessandra
- Montini, Eugenio
- Fumagalli, Francesca
- Plati, Tiziana
- Baldoli, Cristina
- Martino, Sabata
- Calabria, Andrea
- Benedicenti, Fabrizio
- Biasco, Luca
- Leo, Simone
- Zanetti, Gianluigi
- Rizzo, William B.
- Cicalese, Maria Pia
- Boelens, Jaap J.
- Schmidt, Manfred
- Neduva, Victor
- Stupka, Elia
- Ciceri, Fabio
- Rovelli, Attilio
- Roncarolo, Maria Grazia
- Aiuti, Alessandro
- Sessa, Maria
- Naldini, Luigi
- Venue
- Science
- Published
- 2013-08-23
- Volume
- 341
- Issue
- 6148
- Pages
- 1233158-1233158
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2089319449
- Cited by
- 1,180
- References
- 62
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 64 · 2023: 62 · 2022: 60 · 2021: 74 · 2020: 92 · 2019: 101 · 2018: 98 · 2017: 109 · 2016: 133 · 2015: 147 · 2014: 133 · 2013: 31
- FWCI
- 97.94
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- metachromatic leukodystrophy, Wiskott-Aldrich syndrome, lentiviral vectors, hematopoietic stem cell gene therapy, ex vivo gene transfer, leukemia risk, HSC engraftment, neurodegenerative diseases, immunodeficiency, disease progression
- MeSH terms
- Brain, Cerebroside-Sulfatase, DNA Damage, Follow-Up Studies, Genetic Engineering, Genetic Vectors, Hematopoietic Stem Cells, Humans, Leukodystrophy, Metachromatic, Magnetic Resonance Imaging, Transduction, Genetic, Genetic Therapy, Lentivirus, Virus Integration, Treatment Outcome, Hematopoietic Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.